Type 2 diabetes mellitus, cognitive impairment and dementia

Diabetic Medicine

Volumn 16, Issue 2, 1999, Pages 93-112

  Stewart, R ^a,b   Liolitsa, D ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b Section of Old Age Psychiatry   (United Kingdom)

Author keywords

Advanced glycation end products; Alzheimer's disease; Apolipoprotein E; Cerebrovascular disease; Cognitive decline; Cognitive impairment; Dementia; Dyslipidaemia; Hyperglycaemia; Hypertension; Hypoglycaemia; I nsulin resistance; Mixed dementia; Post stroke dementia; Type 2 diabetes mellitus; Vascular dementia

Indexed keywords

ALZHEIMER DISEASE; COGNITIVE DEFECT; COMORBIDITY; DISEASE ASSOCIATION; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; MULTIINFARCT DEMENTIA; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; RISK ASSESSMENT;

CASE-CONTROL STUDIES; COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; DEMENTIA; DIABETES MELLITUS, TYPE 2; HUMANS; POPULATION SURVEILLANCE; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 0032707190     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.1999.00027.x     Document Type: Review

References (145)

1. 1 Breteler MMB, Claus JJ, Grobbee DE, Hofman A. Cardiovascular disease and distribution of cognitive function in elderly people: the Rotterdam study. Br Med J 1994; 308: 1604-1608.
2. 2 Kalmijn S, Feskens EJM, Launer LJ, Kromhout D. Cerebrovascular disease, the apolipoprotein e4 allele, and cognitive decline in a community-based study of elderly men. Stroke 1996; 27: 2230-2235.
3. 3 Hofman A, Ott A, Breteler MMB, Bots ML, Slooter AJC, van Harskamp F et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 1997; 349: 151-154.
4. 4 Meuter F, Thomas W, Grüneklee D, Gries FA, Lohmann R. Psychometric evaluation of performance in diabetes mellitus. Horm Metab Res 1980; 9: 9-17.
5. 5 Perlmuter LC, Hakami MK, Hodgson-Harrington C, Ginsberg J, Katz J, Singer DF. et al. Decreased cognitive function in aging non-insulin-dependent diabetic patients. Am J Med 1984; 77: 1043-1048.
6. 6 Mattlar C-E, Falck B, Rönnemaa T, Hyyppä MT. Neuropsychological cognitive performance of patients with type-2 diabetes. Scand J Rehab Med 1985; 17: 101-105.
7. 7 Robertson-Tchabo EA, Arenberg D, Tobin JD, Plotz JB. A longitudinal study of cognitive performance in noninsulin dependent diabetic men. Exp Gerontol 1986; 21: 459-467.
8. 8 Perlmuter LC, Tun P, Sizer N, McGlinchey RE, Nathan DM. Age and diabetes related changes in verbal fluency. Exp Aging Res 1987; 13: 9-14.
9. 9 Mooradian AD, Perryman K, Fitten J, Kavonian GD, Morley JE. Cortical function in elderly non-insulin dependent diabetic patients. Arch Intern Med 1988; 148: 2369-2372.
10. 10 Cerizza M, Minciotti G, Meregalli S, Garosi V, Crosti PF, Frattola L. Central nervous system involvement in elderly patients with non-insulin-dependent diabetes mellitus. Acta Diabetol Lat 1990; 27: 343-348.
11. 11 Reaven GM, Thompson LW, Nahum D, Haskins E. Relationship between hyperglycemia and cognitive function in older NIDDM patients. Diabetes Care 1990; 13: 16-21.
12. 12 U'Ren RC, Riddle MC, Lezak MD, Bennington-Davis M. The mental efficiency of the elderly person with type II diabetes mellitus. J Am Ger Soc 1990; 38: 505-510.
13. 13 Jagusch W, v. Cramon Renner R, Hepp KD. Cognitive function and metabolic state in elderly diabetic patients. Diab Nutr Metab 1992; 5: 265-274.
14. 14 Soininen H, Puranen M, Helkala E-L, Laakso M, Riekkinen PJ. Diabetes mellitus and brain atrophy: a computerised tomography study in an elderly population. Neurobiol Aging 1992; 13: 717-721.
15. 15 Gradman TJ, Laws A, Thompson LW, Reaven GM. Verbal learning and/or memory improves with glycemic control in older subjects with non-insulin-dependent diabetes mellitus. J Am Ger Soc 1993; 41: 1305-1312.
16. 16 Mooradian AD, Silverley FD. Qualitative differences in the visual retention test performance of older non-insulin-dependent diabetic patients. Age 1993; 16: 67-69.
17. 17 Worrall G, Moulton N, Briffett E. Effect of type II diabetes mellitus on cognitive function. J Fam Pract 1993; 36: 639-643.
18. 18 Lowe LP, Tranel D, Wallace RB, Welty TK. Type II diabetes and cognitive function: a population-based study of Native Americans. Diabetes Care 1994; 17: 891-896.
19. 19 Tetsutani T, Yamaguchi T, Kadono K, Takahara N, Nishimura T, Kaneko M. Detection of cerebrovascular disease in diabetic patients by means of the Kana test. Current Therapeutic Research 1994; 55: 1247-1254.
20. 20 Atiea JA, Moses JL, Sinclair AJ. Neuropsychological function in older subjects with non-insulin-dependent diabetes mellitus. Diabetic Medicine 1995; 12: 679-685.
21. 21 Helkala E-L, Niskanen L, Viinamaki H, Partanen J, Uusitupa M. Short-term and long-term memory in elderly patients with NIDDM. Diabetes Care 1995; 18: 681-685.
22. 22 Zaslavsky LMA, Gross JL, Chaves ML, Machado R. Memory dysfunction and autonomic neuropathy in non-insulin-dependent (type 2) diabetic patients. Diabetes Res Clin Pract 1995; 30: 101-110.
23. 23 Assisi A, Alimenti M, Maceli F, Di Pietro S, Lalloni G, Montera P. Diabetes and cognitive function: preliminary studies. Arch Gerontol Geriatr 1996; 23 (Suppl. 5): 229-232.
24. 24 Motta M, Sorace S, Restuccia S, Carnazzo G, Corrao G, Seminara G et al. Cognitive impairment in the elderly diabetics. Arch Gerontol Geriatr 1996; 23 (Suppl. 5): 43-46.
25. 25 Dey J, Misra A, Desai NG, Mahapatra AK, Padma MV. Cognitive function in younger type II diabetes. Diabetes Care 1997; 20: 32-35.
26. 26 Strachan MWJ, Deary IJ, Ewing FME, Frier BM. Is type II diabetes associated with on increased risk of cognitive dysfunction? Diabetes Care 1997; 20: 438-445.
27. 27 Bourdel-Marchasson I, Dubroca B, Manciet G, Decamps A, Emeriau J-P, Dartigues J-F. Prevalence of diabetes and effect on quality of life in older French living in the community: the PAQUID study. J Am Geriatr Soc 1997; 45: 295-301.
28. 28 Waldstein SR, Manuck SB, Ryan CM, Muldoon MF. Neuropsychological correlates of hypertension: review and methodologic considerations. Psychological Bull 1991; 110: 451-468.
29. 29 Dufouil C, Fuhrer R, Dartigues J-F, Alpérovitch A. Longitudinal analysis of the association between depressive symptomatology and cognitive deterioration. Am J Epidemiol 1996; 144: 634-641.
30. 30 Strachan MWJ, Frier BM, Deary IJ. Cognitive assessment in diabetes: the need for consensus. Diabetic Med 1997; 14: 421-422.
31. 31 Bäckman L, Hill RD, Forsell Y. The influence of depressive symptomatology on episodic memory functioning among clinically nondepressed older adults. J Abn Psychol 1996; 105: 97-105.
32. 32 La Rue A, Swan GE, Carmelli D. Cognition and depression in a cohort of aging men: results from the Western Collaborative Group Study. Psychol Aging 1995; 10: 30-33.
33. 33 Scherr PA, Albert MS, Funkenstein HH, Cook NR, Hennekens CH, Branch LG et al. Correlates of cognitive function in an elderly community population. Am J Epidemiol 1988; 128: 1084-1101.
34. 34 Launer LJ, Dinkgreve MAHM, Jonker C, Hooijer C, Lindeboom J. Are age and education independent correlates of the mini-mental state exam performance of community-dwelling elderly? J Gerontol 1993; 48: P271-P277.
35. 35 Breteler MMB. Cognitive Decline in the Elderly. Published Thesis, ISBN 90-90006241-6 1993.
36. 36 Mangione CM, Seddon JM, Cook EF et al. Correlates of cognitive function scores in elderly outpatients. J Am Ger Soc 1993; 41: 491-497.
37. 37 Desmond DW, Tatemichi TK, Paik M, Stern Y. Risk factors for cerebrovascular disease as correlates of cognitive function in a stroke-free cohort. Arch Neurol 1993; 50: 162-166.
38. 38 Woo J, Ho SC, Lau S, Lau J, Yuen YK. Prevalence of cognitive impairment and associated factors among elderly Hong Kong Chinese aged 70 years and older. Neuroepidemiology 1994; 13: 50-58.
39. 39 Croxson SCM, Jagger C. Diabetes and cognitive impairment: a community-based study of elderly subjects. Age Ageing 1995; 24: 421-424.
40. 40 Kalmijn S, Feskens EJ, Launer LJ, Stijnen T, Kromhout D. Glucose intolerance, hyperinsulinaemia and cognitive function in a general population of elderly men. Diabetologia 1995; 38: 1096-1102.
41. 41 Amato L, Paolisso G, Cacciatore F, Ferrara N, Canonico S, Rengo F et al. Non-insulin-dependent diabetes mellitus is associated with a greater prevalence of depression in the elderly. Diabetes Metab 1996; 22: 314-318.
42. 42 Kilander L, Nyman H, Boberg M, Lithell H. Cognitive function, vascular risk factors and education. A cross-sectional study based on a cohort of 70-year-old men. J Intern Med 1997; 242: 313-321.
43. 43 van Boxtel MPJ, Buntinx F, Houx PJ, Metsemakers JFM, Knottnerus A, Jolles J. The relation between morbidity and cognitive performance in a normal aging population. J Gerontol 1998; 53: M147-M154.
44. 44 Elias PK, Elias MF, D'Agostino RB, Cupples LA, Wilson PW, Silbershatz H et al. NIDDM and blood pressure as risk factors for poor cognitive performance. Diabetes Care 1997; 20: 1388-1395.
45. 45 Harris MI, Hadden WC, Knowler WC, Bennett PH. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. population aged 20-74 yr. Diabetes 1987; 36: 523-534.
46. 46 Ott A, Stolk RP, Hofman A, van Harskamp F, Grobbee DE, Breteler MMB. Association of diabetes mellitus and dementia: The Rotterdam Study. Diabetologia 1996; 39: 1392-1397.
47. 47 Heyman A, Wilkinson WE, Stafford JA, Helms MJ, Sigmon AH, Weinberg T. Alzheimer's disease: a study of epidemiological aspects. Ann Neurol 1984; 15: 335-341.
48. 48 Broe GA, Henderson AS, Creasey H, McCusker E, Korten AE, Jorm AF et al. A case-control study of Alzheimer's disease in Australia. Neurology 1990; 40: 1698-1707.
49. 49 Ferini-Strambi L, Smirne S, Garancini P, Pinto P, Franceschi M. Clinical and epidemiological aspects of Alzheimer's disease with presenile onset: a case control study. Neuroepidemiology 1990; 9: 39-49.
50. 50 Meyer JS, McClintic KL, Rogers RL, Sims P, Mortel KF. Aetiological considerations and risk factors for multi-infarct dementia. J Neurol Neurosurg Psych 1988; 51: 1489-1497.
51. 51 Lindsay J, Hébert R, Rockwood K. The Canadian Study of Health and Aging: risk factors for vascular dementia. Stroke 1997; 28: 526-530.
52. 52 Wolf-Klein GP, Silverstone FA, Brod MS, Levy A, Foley CJ, Termotto Breuer J. Are Alzheimer patients healthier? J Am Geriatr Soc 1988; 36: 219-224.
53. 53 Landin K, Blennow K, Wallin A, Gottfries C-G. Low blood pressure and blood glucose levels in Alzheimer's disease. Evidence for a hypometabolic disorder? J Int Med 1993; 233: 357-363.
54. 54 Mortel KF, Wood S, Pavol MA, Meyer JS, Rexer JL. Analysis of familial and individual risk factors among patients with ischemic vascular dementia and Alzheimer's disease. Angiology 1993; 44: 599-605.
55. 55 Kielson KA, Nolan JF, Berchtold NC, Sandman CA, Mulnard RA, Cotman CW. Apolipoprotein-E genotyping of diabetic dementia patients: is diabetes rare in Alzheimer's disease? J Am Geriatr Soc 1996; 44: 897-904.
56. 56 Gorelick PB, Brody J, Cohen D, Freels S, Levy P, Dollear W et al. Risk factors for dementia associated with multiple cerebral infarcts. Arch Neurol 1993; 50: 714-720.
57. 57 McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944.
58. 58 Loeb C, Gandolfo C, Croce R, Conti M. Dementia associated with lacunar infarction. Stroke 1992; 23: 1225-1229.
59. 59 Tatemichi TK, Desmond DW, Paik M, Fogueroa M, Gropen TI, Stern Y et al. Clinical determinants of dementia related to stroke. Ann Neurol 1993; 33: 568-575.
60. 60 Kokeman F, Whistman JP, O'Fallon WM, Chu CP, Beard CM. Dementia after ischemic stroke: a population-based study in Rochester, Minnesota (1960-84). Neurology 1996; 19: 154-159.
61. 61 Censori B, Manara O, Agostinis C, Camerlingo M, Casto L, Galavotti B et al. Dementia after first stroke. Stroke 1996; 27: 1205-1210.
62. 62 Pohjasvaara T, Erkinjuntti T, Ylikoski R, Hietanen M, Vataja R, Kaste M. Clinical determinants of poststroke dementia. Stroke 1998; 29: 75-81.
63. 63 Yoshitake T, Kiyohara Y, Kato I, Ohmura T, Iwamoto H, Nakayama K et al. Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population: the Hisayama Study. Neurology 1995; 45: 1161-1168.
64. 64 Ott A, Stolk RP, van Harskamp F, Hofman A, Breteler MMB. Diabetes mellitus and the risk of dementia in an elderly population. In Ott A ed. Risk of Dementia. Delft: Judels En Brinkman BV, 1997: 49-62.
65. 65 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 3rd edn. Washington, DC: American Psychiatric Association, 1987.
66. 66 Leibson CL, Rocca WA, Hanson VA, Cha R, Kokmen E, O'Brien PC et al. Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am J Epidemiol 1997; 145: 301-308.
67. 67 Breckenridge A. Angiotensin converting enzyme inhibitors and quality of life. Am J Hypertens 1991; 4: 79S-82S.
68. 68 Prince MJ, Bird AS, Blizard RA, Mann AH. Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's treatment trial of hypertension in older adults. Br Med J 1996; 312: 801-804.
69. 69 Fletcher A, Bulpitt C. Quality of life in the treatment of hypertension. The effect of calcium antagonists. Drugs 1992; 44: 135-140.
70. 70 Guo Z, Viitanen M, Fratiglioni L, Winblad B. Low blood pressure and dementia in elderly people: the Kungsholmen project. Br Med J 1996; 312: 805-808.
71. 71 Perlmuter LC, Nathan DM, Goldfinger SH, Russo PA, Yates J, Larkin M. Triglyceride levels affect cognitive function in noninsulin dependent diabetics. J Diabetic Complications 1988; 2: 210-213.
72. 72 Koenig W, Sund M, Ernst E, Mraz W, Hombach V, Keil U. Association between rheology and components of lipoproteins in human blood. Circulation 1992; 85: 2197-2204.
73. 73 Newman AB, Enright PL, Manolio TA, Haponik EF, Wahl PW. Sleep disturbance, psychosocial correlates, and cardiovascular disease in 5201 older adults: The Cardiovascular Health Study. J Am Geriatr Soc 1997; 45: 1-7.
74. 74 Prinz PN. Sleep and sleep disorders in older adults. J Clin Neurophysiol 1995; 12: 139-146.
75. 75 Holmes CS, Hayford JT, Gonzalez JL, Weydert JA. A survey of cognitive functioning at different glucose levels in diabetic persons. Diabetes Care 1983; 6: 180-185.
76. 76 Craft S, Dagogo-Jack SE, Wiethop BV, Murphy C, Nevins RT, Fleischman F et al. Effects of hyperglycemia on memory and hormone levels in dementia of the Alzheimer type: a longitudinal study. Behaviour Neurosci 1993; 107: 926-940.
77. 77 Gold AE, Deary IJ, Frier BM. Recurrent severe hypoglycaemia and cognitive function in type 1 diabetes. Diabetic Med 1993; 10: 499-505.
78. 78 Hung J, Menth L, Thompson MJ, Saner B, Venkateswara Rao K, Barbosa J. The Minnesota Diabetes Complications Clinical Trial cognitive functions under long-term maximized and standard metabolic controls. Diabete Metabolisme 1984; 10: 48-51.
79. 79 Reichard P, Pihl M, Rosenqvist U, Sule J. Complications in IDDM are caused by elevated blood glucose level: The Stockholm Diabetes Intervention Study (SDIS) at 10-year follow up. Diabetologia 1996; 39: 1483-1488.
80. 80 The Diabetes Control, Complications Trial Research Group. Effects of intensive diabetes therapy on neuropsychological function in adults in the diabetes control and complications trial. Ann Intern Med 1996; 124: 379-388.
81. 81 Ryan CM, Williams TM, Finegold DN, Orchard TJ. Cognitive dysfunction in adults with Type 1 (insulin dependent) diabetes mellitus of long duration: effects of recurrent hypoglycaemia and other chronic complications. Diabetologia 1993; 36: 329-334.
82. 82 Amiel SA. Diabetes and dementia: a causal association? Diabetic Med 1994; 11: 430-431.
83. 83 Gjedde A, Crone C. Blood-brain glucose transfer: repression in chronic hyperglycemia. Science 1981; 214: 456-457.
84. 84 Matyka K, Evans M, Lomas J, Cranston I, Macdonald I, Amiel SA. Altered hierarchy of protective responses against severe hypoglycemia in normal aging in healthy men. Diabetes Care 1997; 20: 135-141.
85. 85 Hébert R, Brayne C. Epidemiology of vascular dementia. Neuroepidemiology 1995; 14: 240-257.
86. 86 Tatemichi TK, Paik M, Bagiella E, Desmond DW, Stern Y, Seno M et al. Risk of dementia after stroke in a hospitalised cohort: results of a longitudinal study. Neurology 1994; 44: 1885-1891.
87. 87 Ferrucci L, Guralnik JM, Salive ME, Pahor M, Corti M, Baroni M et al. Cognitive impairment and risk of stroke in the older population. J Am Geriatr Soc 1996; 44: 237-241.
88. 88 Hulette C, Nochlin D, McKeel D, Morris JC, Mori SS, Sumi SM et al. Clinical-neuropathologic findings in multi-infarct dementia: a report of six autopsied cases. Neurology 1997; 48: 668-672.
89. 89 Hall ED, Oostveen JA, Dunn E, Carter DB. Increased amyloid protein precursor and apolipoprotein E immunoreactivity in the selectively vulnerable hippocampus following transient forebrain ischemia in gerbils. Exp Neurol 1995; 135: 17-27.
90. 90 Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. J Am Med Assoc 1997; 277: 813-817.
91. 91 Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 1991; 87: 432-438.
92. 92 Vlassara H, Fuh H, Makita Z, Krungkrai S, Cerami A, Bucala R. Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. Proc Natl Acad Sci 1992; 89: 12043-12047.
93. 93 Chew W, Kucharczyk J, Moseley M, Derugin N, Norman D. Hyperglycemia augments ischemic brain injury. Am J Neuroradiol 1991; 12: 603-609.
94. 94 Weir CJ, Murray CJ, Dyker AG, Lees KR. Is hyperglycaemia an independent predictor of poor outcome after acute stroke? Results of a long term follow up study. Br Med J 1997; 314: 1303-1306.
95. 95 McCall AL. The impact of diabetes on the CNS. Diabetes 1992; 41: 557-570.
96. 96 Pirttilä T, Järvenpää R, Laippala P, Frey H. Brain atrophy on computerized axial tomography scans: interaction of age, diabetes and general morbidity. Gerontology 1992; 38: 285-291.
97. 97 Biessels GJ, Kappelle AC, Bravenboer B, Erkelens DW, Gispen WH. Cerebral function in diabetes mellitus. Diabetologia 1994; 37: 643-650.
98. 98 Coyle JT, Price DL, DeLong MR. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 1983; 219: 1184-1190.
99. 99 Mooradian AD. Blood-brain barrier choline transport is reduced in diabetic rats. Diabetes 1987; 36: 1094-1097.
100. 100 Odawara M, Tada K, Yamashita K. Decreased cerebral blood perfusion in an NIDDM patient with an A-to-G mutation in the mitochondrial gene; a possible contribution to cognition deficits in diabetes mellitus (letter). Diabetologia 1995; 38: 1004-1005.
101. 101 Greene DA, Sima AAF, Stevens MJ, Feldman EL, Lattimer SA. Complications: neuropathy, pathogenetic considerations. Diabetes Care 1992; 15: 1902-1925.
102. 102 Sredy J, Sawicki DR, Notvest RR. Polyol pathway activation in nervous tissues of diabetic and galactose-fed rats: effect of dietary galactose withdrawal or tolretat intervention therapy. J Diabetic Complications 1991; 5: 42-47.
103. 103 Sussman I, Carson MP, Schultz V, Wu XP, McCall AL, Ruderman NB et al. Chronic exposure to high glucose decreases myo-inositol in cultured cerebral microvascular pericytes but not in endothelium. Diabetologia 1988; 31: 771-775.
104. 104 Vlassara H, Bucala R, Striker L. Pathogenic effects of advanced glycosylation: Biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest 1994; 70: 138-151.
105. 105 Dickson DW, Sinicropi S, Yen SH, Ko LW, Mattiace LA, Bucala R et al. Glycation and microglial reaction in lesions of Alzheimer's disease. Neurobiol Aging 1996; 17: 733-743.
106. 106 Horie K, Miyata T, Yasuda T, Takeda A, Yasuda Y, Maeda K et al. Immunohistochemical localisation of advanced glycation end products, pentosidine, and carboxymethyllysine in lipofuscin pigments of Alzheimer's disease and aged neurons. Biochem Biophys Res Commun 1997; 236: 327-332.
107. 107 Takeda A, Yasuda T, Miyata T, Mizuno K, Li M, Yoneyama S et al. Immunohistochemical study of advanced glycation end products in aging and Alzheimer's disease brain. Neurosci Lett 1996; 221: 17-20.
108. 108 Finch CE, Cohen DM. Aging, metabolism and Alzheimer's disease: Review and hypotheses. Exp Neurol 1997; 143: 82-102.
109. 109 Li YM, Dickson DW. Enhanced binding of advanced glycation end produces (AGE) by the ApoE4 isoform links the mechanism of plaque deposition in Alzheimer's disease. Neurosci Lett 1997; 226: 155-158.
110. 110 Ledesma MD, Bonay P, Colaco C, Avila J. Analysis of microtubule-associated protein tau glycation in paired helical filaments. J Biol Chem 1994; 269: 21614.
111. 111 Renard C, Chappey O, Wautier M-P, Nagashima M, Lundh E, Morser J et al. Recombinant advanced glycation end product receptor pharmacokinetics in normal and diabetic rats. Mol Pharmacol 1997; 52: 54-62.
112. 112 Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A et al. RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease. Nature 1996; 382: 685-691.
113. 113 Shoda H, Miyata S, Liu B-F, Yamada H, Ohara T, Suzuki K et al. Inhibitory effects of Tenilsetam on the Maillard reaction. Endocrinol 1997; 138: 1886-1892.
114. 114 Heitner J, Dickson D. Diabetics do not have increased Alzheimer-type pathology compared with age-matched control subjects. Neurology 1997; 49: 1306-1311.
115. 115 Cooper GJS, Willis AC, Clark A, Turner RC, Sim RB, Reid KB. Purification and characterisation of a peptide from amyloi-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci USA 1987; 84: 8628-8632.
116. 116 Dore S, Kar S, Quirion R. Insulin-like growth factor I protects and rescues hippocampal neurons against β-amyloid-and human amylin-induced toxicity. Proc Natl Acad Sci USA 1997; 94: 4772-4777.
117. 117 Edgington SM. Amyloid plaque and diabetes. New research suggests Alzheimer's disease and type II diabetes share a similar pathology. Bio/Technol 1994; 12: 591-594.
118. 118 Wickelgren I. Tracking insulin to mind. Science 1998; 280: 517-519.
119. 119 Marks JL, King MG, Baskin DG. Localisation of insulin and type 1 IGF receptors in rat brain by in vitro autoradiography and in situ hybridisation. Adv Exp Med Biol 1991; 293: 459-470.
120. 120 Seab JP, Jagust WJ, Wong STS, Roos MS, Reed BR, Budinger TF. Quantitative NMR measurements of hippocampal atrophy in Alzheimer's disease. Magn Reson Med 1988; 8: 200-208.
121. 121 Palovcik RA, Phillips MI, Kappy MS, Raizada MK. Insulin inhibits pyramidal neurons in hippocampal slices. Brain Res 1984; 309: 187-191.
122. 122 Brass BJ, Nonner D, Barrett JN. Differential effects of insulin on choline acetyltransferase and glutamic acid decarboxylase activities in neuron-rich striatal cultures. J Neurochem 1992; 59: 415-424.
123. 123 Cross DAE, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 mediated by protein kinase B. Nature 1995; 378: 785-789.
124. 124 Eldar-Finkelman H, Argast GM, Foord O, Fischer EM, Krebs EG. Expression of glycogen synthase kinase-3 mutants in cells and their effects on glycogen synthase activity in intact cells. Proc Natl Acad Sci USA 1996; 93: 10228-10233.
125. 125 Lawrence JC, Roach PJ. New insights into the role and mechanism of glycogen synthase activation by insulin. Diabetes 1997; 46: 541-547.
126. 126 Moxham CM, Tabrizchi A, Davis RJ, Malbon C. jun N-terminal kinase mediates activation of skeletal muscle glycogen synthase by insulin in Vivo J Biol Chem 1996; 271: 30765-30773.
127. 127 Horst-Sikorska W, Zoll B, Kwiatkowska J, Willms B, Kraszewski A, Horst A et al. Prevalence of beta allele of the insulin gene in type II diabetes mellitus. Hum Genet 1994; 93: 325-328.
128. 128 Almind K, Inoue G, Pedersen O, Kahn CR. A common amino acid polymorphism in insulin receptor substrate-1 causes impaired insulin signalling. J Clin Invest 1996; 97: 2569-2575.
129. 129 Sigal RJ, Doria A, Warram JH, Krolewski AS. Codon 972 polymorphism in the insulin receptor subsstrate-1 gene, obesity, and risk of noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1996; 81: 1657-1659.
130. 130 Hansen L, Hansen T, Vestergaard H, Bjorbaek C, Echwald SM, Clausen JO et al. A widespread amino acid polymorphism at codon 905 of the glycogen-associated regulatory subunit of protein phosphatase-1 is associated with insulin resistance and hypersecretion of insulin. Hum Mol Genet 1995; 4: 1313-1320.
131. 131 Hansen L, Rasmussen SB, Viars CS, Viars CS, Vestergaard H, Hansen T et al. Chromosomal mapping and mutational analysis of the coding region of glycogen synthase kinase-3α and isoforms in patients with NIDDM. Diabetolagia 1997; 40: 940-946.
132. 132 Lovestone S, Reynolds CH. The phosphorylation of tau: a critical stage in neurodevelopment and neurodegenerative processes. Neuroscience 1997; 78: 309-324.
133. 133 Hong M, Lee VMY. Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons. J Biol Chem 1997; 272: 19547-19553.
134. 134 Reaven GM. Role of Insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
135. 135 Stolk RP, Breteler MMB, Ott A, Pols HAP, Lamberts SWJ, Grobbee DE et al. Insulin and cognitive function in an elderly population. Diabetes Care 1997; 20: 792-795.
136. 136 Kuusisto J, Koivisto K, Mykkanen L, Helkala E, Vanhanen M, Hänninen T et al. Essential hypertension and cognitive function: the role of hyperinsulinemia. Hypertension 1993; 22: 771-779.
137. 137 Meneilly GS, Hill A. Alterations in glucose metabolism in patients with Alzheimer's disease. J Am Geriatr Soc 1993; 41: 710-714.
138. 138 Kuusisto J, Koivisto K, Mykkänen L, Helkala E, Vanhanen M, Hänninen T et al. Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study. BMJ 1997; 315: 1045-1049.
139. 139 Noguchi S, Murakami K, Yamada N. Apolipoprotein E genotype and Alzheimer's disease. Lancet 1993; 342: 737.
140. 140 Uusitupa MIJ, Karhunen L, Rissanen A, Fransilla-Kaluncki A, Niskanen L, Kervinen K et al. Apolipoprotein E phenotype modifies metabolic and hemodynamic abnormalities related to central obesity in women. Am J Clin Nutr 1996; 64: 131-136.
141. 141 Ukkola O, Kervinen K, Salmela PI, von Dickhoff K, Laakso M, Kesäniemi YA. Apolipoprotein E phenotype is related to macro-and microangiopathy in patients with non-insulin-dependent diabetes mellitus. Atherosclerosis 1993; 101: 9-15.
142. 142 Meneilly GS, Cheung E, Tessier D, Yakura C, Tuokko H. The effects of improved glycemic control on cognitive functions in the elderly patient with diabetes. J Geront 1993; 48: M117-M121.
143. 143 Naor M, Steingrüber HJ, Westhoff K, Schottenfeld-Naor Y, Gries AF. Cognitive function in elderly non-insulin-dependent diabetic patients before and after inpatient treatment for metabolic control. J Diabetes Complications 1997; 11: 40-46.
144. 144 Rost K, Roter D, Quill T, Bertakis K. Capacity to remember prescription drug changes: deficits associated with diabetes. Diabetes Res Clin Pract 1990; 10: 183-187.
145. 145 Katzman R, Aronson M, Fuld P, Kawas C, Brown T, Morgenstern H et al. Development of dementing illness in an 80-year-old volunteer cohort. Ann Neurol 1989; 25: 317-324.